

**Amendments to the Claims:**

This listing of claims will replace all prior versions and listings of claims in the application.

Claims 1-65 (Cancelled)

66. (New) An isolated polypeptide comprising:
- a) the amino acid sequence of SEQ ID NO. 2 or
  - b) the amino acid sequence of amino acids 24 through 189 of SEQ ID NO. 2;  
wherein said sequence comprises a G45R SNP.
67. (New) A composition comprising the polypeptide of claim 66 and at least one excipient.
68. (New) The composition of claim 67, wherein said excipient is a pharmaceutically acceptable excipient.
69. (New) The composition of 67, wherein said excipient is a buffer, aqueous vehicle, non-aqueous vehicle, wetting agent, dispersant, emulsifier, or preservative.
70. (New) A pharmaceutical composition comprising the polypeptide of claim 66 and a pharmaceutically acceptable excipient.
71. (New) The pharmaceutical composition of 70, wherein said excipient is a buffer, aqueous vehicle, non-aqueous vehicle, wetting agent, dispersant, emulsifier, or preservative.

72. (New) An isolated polypeptide comprising an amino acid sequence at least 95% identical to
- a) the amino acid sequence of SEQ ID NO. 2 or
  - b) the amino acid sequence of amino acids 24 through 189 of SEQ ID NO. 2;
- wherein said sequence comprises a G45R SNP and said polypeptide exhibits at least one antiviral activity, antiproliferative activity, or immunomodulatory activity;
- wherein said antiviral activity is against vesicular stomatitis virus or encephalomyocarditis virus;
- wherein said antiproliferative activity is against TF-1 or Daudi Burkitt's cell line;
- wherein said immunomodulatory activity is dendritic cell maturation, cytokine release by monocytes, CD4+ T-lymphocytes, or CD8+ T-lymphocytes.
73. (New) The polypeptide of claim 72, wherein said amino acid sequence is at least 97% identical to the amino acid sequence SEQ ID NO: 2.
74. (New) The polypeptide of claim 72, wherein said amino acid sequence is at least 99% identical to the amino acid sequence SEQ ID NO: 2.
75. (New) The polypeptide of claim 72, wherein said amino acid sequence is at least 97% identical to the amino acid sequence of amino acids 24 through 189 of SEQ ID NO. 2.
76. (New) The polypeptide of claim 72, wherein said amino acid sequence is at least 99% identical to the amino acid sequence of amino acids 24 through 189 of SEQ ID NO. 2.
77. (New) A composition comprising the polypeptide of claim 72 and at least one excipient.
78. (New) The composition of claim 77, wherein said excipient is a pharmaceutically acceptable excipient.

79. (New) The composition of 77, wherein said excipient is a buffer, aqueous vehicle, non-aqueous vehicle, wetting agent, dispersant, emulsifier, or preservative.
80. (New) A pharmaceutical composition comprising the polypeptide of claim 72 and a pharmaceutically acceptable excipient.
81. (New) The pharmaceutical composition of 80, wherein said excipient is a buffer, aqueous vehicle, non-aqueous vehicle, wetting agent, dispersant, emulsifier, or preservative.